This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): L-NDDP
Description: Aroplatin is a liposomal formulation of an advanced platinum chemotherapeutic similar to Eloxatin. Aroplatin is designed to overcome the toxicity and drug resistance associated with current platinum-based chemotherapeutics. Research has shown that liposome encapsulation can increase a treatment’s bioavailability, extending the treatment’s effect; help reduce the damaging effects of some drugs on healthy tissues, markedly improving a treatment’s safety profile; and accumulate at the site of a tumor, delivering higher concentrations of the drug to the disease target.
Deal Structure: Aroplatin was originally developed by Aronex.
In 2001, Antigenics acquired Aronex.
Additional information available to subscribers only: